Amarin Shareholders Invited to Webcast with Board and Management Team

— Board and Management Team to Answer Shareholder Questions —

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that members of its Board of Directors and management team will host a live webcast on Tuesday, February 14, 2023, from 8:00 a.m. – 9:00 a.m. ET. The webcast will be a question-and-answer session where the Company will answer some of the most common shareholder questions focused on Amarin’s strategy and what the refreshed Board and management team are doing to drive operational and financial improvements and enhance value for all shareholders.

Amarin shareholders are encouraged to submit questions in advance to

Amarin participants include:

  • Per Wold-Olsen, Independent Chairman of the Board and Chair of the Remuneration Committee
  • Adam Berger, Independent Director and Chair of the Nominating and Corporate Governance Committee
  • Erin Enright, Independent Director and Chair of the Audit Committee
  • Karim Mikhail, President and Chief Executive Officer

Webcast Information

To access the webcast, go to or visit the shareholder resources section of

General Meeting Information

As previously announced, Amarin’s upcoming General Meeting of Shareholders is scheduled to be held on February 28, 2023, and shareholders of record as of January 23, 2023, will be entitled to vote at the meeting.

Amarin’s Board of Directors urges shareholders to vote “AGAINST” all proposals on the WHITE proxy card. For ADS holders, the deadline to submit your vote is 3 PM GMT (10 AM ET) February 22, 2023, and for holders of ordinary shares, the deadline is 3 PM GMT (10 AM ET) February 24, 2023.

Amarin shareholders who need assistance in voting their shares may call Amarin’s proxy solicitors, Morrow Sodali at 1 (800) 662-5200 or Okapi Partners at 1 (844) 343-2625.

Additional information can be found at

About Amarin

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.

Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to U.S. federal securities law. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the full year ended 2021, and Amarin’s quarterly reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022, and September 30, 2022, and its other filings. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.

Amarin Contact Information

Investor Inquiries:
Lisa DeFrancesco
Investor Relations Amarin Corporation plc (investor inquiries)

Media Inquiries:
Mark Marmur
Corporate Communications, Amarin Corporation plc (media inquiries)


Steve Frankel / Andi Rose / Tali Epstein
Joele Frank, Wilkinson Brimmer Katcher

error: Content is protected !!